QPPV Support Essentials

A Qualified Person Responsible for Pharmacovigilance (QPPV) is not merely a named contact on a regulatory form. The role connects patient-safety evidence, the certificate of registration holder’s management system, and local regulatory oversight. Effective QPPV support must therefore provide authority, access, continuity, and documented control.

What the organisation must enable

Accountability remains with the certificate of registration holder even when QPPV services are outsourced. Management should give the QPPV direct access to senior decision-makers, product information, safety databases or outputs, contracts, compliance data, audit reports, CAPA plans, and planned business changes that may affect the pharmacovigilance system.

The QPPV should be involved early when the organisation adds products, appoints or changes distributors, acquires a portfolio, starts a patient programme, or changes its safety database. Late notification can create gaps in case transfer, product coverage, or reporting responsibility.

Core QPPV responsibilities

The QPPV needs an overview of product safety profiles and emerging concerns, as well as oversight of SOPs, training, contractual arrangements, database operations, expedited reporting, periodic reports, audits, and compliance performance. The role also functions as a pharmacovigilance contact for NAFDAC and for inspections.

This does not mean that the QPPV personally performs every activity. Specific tasks may be delegated to trained personnel, but the delegation should be documented and the QPPV should retain system oversight. A responsibility matrix should separate accountability from execution and identify who acts when the primary QPPV is unavailable.

For teams preparing for a NAFDAC review, the NAFDAC QPPV Compliance Checklist can be used alongside QPPV support to document readiness and evidence retention.

The minimum documentation set

A support model should maintain, at minimum: the QPPV’s current curriculum vitae and contact details; approved job description; proof of relevant training; QPPV and backup appointment records; an availability and escalation procedure; a delegation log; the current product list; the PSMF; safety-data exchange agreements; SOPs; compliance dashboards; audit and CAPA records; and evidence of regulatory notifications.

The PSMF should reflect the operating system, not an idealised description. A scheduled PSMF review should be supplemented by event-driven updates after material changes.

Oversight that can be demonstrated

A practical QPPV dashboard should show case receipt and submission timeliness, overdue follow-up, partner reconciliation status, periodic report commitments, open signals, training completion, audit findings, CAPA ageing, and upcoming regulatory obligations. Each indicator should have a defined denominator, threshold, owner, and escalation rule.

Vendor oversight requires more than a signed contract. The QPPV should receive performance evidence, review reconciliation outputs, assess deviations, and confirm that corrective action is effective. An outsourced activity must therefore remain visible and auditable.

A workable support model

Before appointing QPPV support, an organisation should confirm product scope, data sources, case volume, local and global interfaces, system access, medical-review arrangements, reporting responsibilities, working hours, backup coverage, and change-notification expectations. The agreement should state how urgent safety issues reach authorised decision-makers without delay.

The strongest QPPV arrangement is measured by how the system behaves: safety information is captured, decisions are timely, records are retrievable, partners are controlled, and management acts on emerging risk. Naming a QPPV is the beginning of local oversight, not the completion of it.

MedNova supports pharmacovigilance, regulatory consulting, regulatory intelligence, medical information, and resource planning for companies seeking practical support for local oversight and ongoing compliance.

References

1. National Agency for Food and Drug Administration and Control. Guidelines for Qualified Person for Pharmacovigilance. Published 2024. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PVG_GUIDELINES/Guidelines-For-Qualified-Person-For-Pharmacovigilance-1.pdf
2. National Agency for Food and Drug Administration and Control. Good pharmacovigilance practice guidelines. Effective January 21, 2021. Accessed July 18, 2026. https://www.nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PVG_GUIDELINES/NAFDAC-Guidelines-on-Good-Pharmacovigilance-2021.pdf
3. National Agency for Food and Drug Administration and Control. Pharmacovigilance inspection guidelines for Nigeria regulated drugs. Published October 15, 2024. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PVG_GUIDELINES/Pharmacovigilance-Inspection-Guidelines-For-Nigeria-Regulated-Drugs.pdf